Cited by 175Cancer, Hypoxia, and MetabolismEar and Head TumorsErythropoietin and Anemia Treatment

The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.

The VHL Tumor Suppressor: Master Regulator of HIF

Open access

Haase, Volker·2009·Current Pharmaceutical Design

DOI 10.2174/138161209789649394PMC PMC3622710

Open this paper in CoChat — free account

Abstract

Hypoxia-Inducible Factors (HIFs) are heterodimeric oxygen-sensitive basic helix-loop-helix transcription factors that play central roles in cellular adaptation to low oxygen environments. The von-Hippel Lindau tumor suppressor (pVHL) is the substrate recognition component of an E3 ubiquitin ligase and functions as a master regulator of HIF activity by targeting the hydroxylated HIF-alpha subunit for ubiquitylation and rapid proteasomal degradation under normoxic conditions. Mutations in pVHL can be found in familial and sporadic hemangioblastomas, clear cell carcinomas of the kidney, pheochromocytomas and inherited forms of erythrocytosis, illustrating the importance of disrupted molecular oxygen sensing in the pathogenesis of these diseases. Tissue-specific gene targeting of pVHL in mice has demonstrated that efficient execution of HIF proteolysis is critically important for normal tissue physiology, and has provided novel insights into the functional consequences of HIF activation on the cellular and tissue level. Here we focus on the contribution of individual HIF transcription factors to the development of VHL phenotypes and discuss how the pVHL/HIF axis could be exploited pharmacologically.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2174/138161209789649394

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914 · cited 1×
“They regulate gene expression by binding to hypoxia-response elements (HREs), specific DNA recognition sequences located in hypoxia enhancer containing regulatory regions of HIF target genes, and consist of an oxygen-sensitive αsubunit and a constitutively expressed β-subunit, also known as the arylhydrocarbon recepto…”
Background
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
Hypoxia-inducible Factor 1α (HIF-1α) Protein Is Rapidly Degraded by the Ubiquitin-Proteasome System under Normoxic Conditions
Salceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
von Hippel-Lindau disease
Lonser, R. R., Glenn, G. M., Walther, M. M., Chew, E. Y., Libutti, S. K., Linehan, W. M., & Oldfield, E. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13643-4 · Cited by 1,630

Show all 114 references

Sorted by citations

Items 101–174 of 174

Virus–Host Protein–Protein Interactions between Human Papillomavirus 16 E6 A1 and D2/D3 Sub-Lineages: Variances and Similarities
Dayer, G., Masoom, M. L., Togtema, M., & Zehbe, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217980 · Cited by 8
The Multifaceted Role of CMA in Glioma: Enemy or Ally?
Dico, A. L., Martelli, C., Diceglie, C., & Ottobrini, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042217 · Cited by 9
Combination therapy of HIFα inhibitors and Treg depletion strengthen the anti‐tumor immunity in mice
Wei, P., Kou, W., Riaz, F., Zhang, K., Fu, J. L., & Pan, F. (2023) · European Journal of Immunology · doi:10.1002/eji.202250182 · Cited by 9
Nonstop mutations cause loss of renal tumor suppressor proteins VHL and BAP1 and affect multiple stages of protein translation
Pal, J., Riester, M., Ganner, A., Ghosh, A., Dhamija, S., Mookherjee, D., Voss, C., Frew, I. J., Kotsis, F., Neumann‐Haefelin, E., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr6375 · Cited by 8
“The tumor suppressor protein VHL is a part of an E3-ubiquitin ligase complex and is involved in hypoxia-related cellular signaling pathways ( 31 ).”
Computational insights into marine-derived pVHL-HIF1 α inhibitors: pharmacophore modelling, molecular docking, MD simulations, MM/PBSA and DFT studies
Prajapati, A., Kachhadiya, R. N., Pravin, M. A., Singh, S. K., & Patel, H. D. (2025) · Molecular Simulation · doi:10.1080/08927022.2025.2574641 · Cited by 8
“Dysfunctional VHL has been linked to the onset of ischaemia, prolonged anaemia and cardiovascular disease [24].”
Deletion of Vhl in Dmp1-Expressing Cells Causes Microenvironmental Impairment of B Cell Lymphopoiesis
Chicana, B. J., Abbasizadeh, N., Burns, C. S., Taglinao, H., Spencer, J. A., & Manilay, J. O. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.780945 · Cited by 7
Potential anti-cancer activity of Moringa oleifera derived bio-active compounds targeting hypoxia-inducible factor-1 alpha in breast cancer
Masarkar, N., Ray, S. K., Saleem, Z., & Mukherjee, S. (2023) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2023-0182 · Cited by 8
Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy
Jackson, W., Yang, Y., Salman, S., Dordai, D. I., Lyu, Y., Datan, E., Drehmer, D., Huang, T. Y.-T., Hwang, Y., & Semenza, G. L. (2024) · Science Advances · doi:10.1126/sciadv.adq2366 · Cited by 9
Loss of PIG3 increases HIF-1α level by promoting protein synthesis via mTOR pathway in renal cell carcinoma cells
Chen, G., Xu, J., Chen, J., Zhang, J.-X., Zhou, J., Liang, Y., & Ding, X. (2016) · Oncotarget · doi:10.18632/oncotarget.8401 · Cited by 7
“In normoxia, hydroxylation of two proline residues and acetylation of a lysine residue in its oxygen-dependent degradation domain (ODDD) promote the association of HIF-1α with the von Hippel-Lindau (pVHL) ubiquitin E3 ligase complex, leading to HIF-1α degradation via ubiquitin-proteasome pathway [7-9].”
Background
Protein Interaction Domains and Post-Translational Modifications: Structural Features and Drug Discovery Applications
Vincenzi, M., Mercurio, F. A., & Leone, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190620101637 · Cited by 8
The protein biosynthesis inhibitor vioprolide A evokes anti-angiogenic and pro-survival actions by targeting NOP14 and decreasing VEGF receptor 2- and TAZ-signaling.
Burgers, L., Li, Y., Michalakis, S., Ciurus, S., Zahler, S., Müller, R., & Fürst, R. (2022) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2022.113174 · Cited by 6
Integrating Surgery in the Multidisciplinary Care of Advanced Renal Cell Carcinoma
Ray, S., Dason, S., & Singer, E. A. (2023) · Urologic Clinics of North America · doi:10.1016/j.ucl.2023.01.013 · Cited by 7
Tissue-dependent VEGF and GLUT1 induction in a rat hemorrhage model: With regard to diagnostic application of mRNA quantification in forensic pathology
Zhao, D. H., Michiue, T., & Maeda, H. (2015) · Forensic Science International · doi:10.1016/j.forsciint.2015.08.007 · Cited by 7
“not through transcriptional regulation at the mRNA level [18–20].”
Background
Association Between VHL Single Nucleotide Polymorphism (rs779805) and the Susceptibility to Prostate Cancer in Chinese
Chen, J., Wu, Y., Shao, P., Cao, Q., Qin, C., Li, P., Ding, Q., Zhu, J., Wang, M., Zhang, Z., et al. (2011) · DNA and Cell Biology · doi:10.1089/dna.2011.1408 · Cited by 7
“…function of pVHL is its role as the substrate recognition submit of an E3 ubiquitin ligase complex and as a master regulator of hypoxia-inducible factor (HIF) activity by targeting the HIF-alpha subunit for ubiquitination and rapid proteasomal degradation under normoxic conditions (Haase, 2009).”
Differential expression of HIF1A and its downstream target VEGFA in the main subtypes of renal cell carcinoma and their impact on patient survival
Strikić, A., Kokeza, J., Ogorevc, M., Kelam, N., Vukoja, M., Đolonga, P., & Tomaš, S. Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1287239 · Cited by 6
“The results of the presented study showed pRCC having higher HIF-1 a protein expression than ccRCC. Previous studies in ccRCC showed that HIF-1 a expression is frequently upregulated due to mutations or inactivation of the VHL gene, which is a common feature in this subtype (5, 14).”
Background
Impact of tissue-agnostic approvals on management of primary brain tumors
Ahluwalia, M. S., Khosla, A. A., Ozair, A., Gouda, M. A., & Subbiah, V. (2024) · Trends in cancer · doi:10.1016/j.trecan.2023.11.005 · Cited by 6
Algorithmic assessment of missense mutation severity in the Von-Hippel Lindau protein
Fields, F. R., Suresh, N., Hiller, M., Freed, S. D., Haldar, K., & Lee, S. W. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234100 · Cited by 6
The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis
Song, G., Xue, S., Zhu, Y., Wu, C., & Ji, X. (2024) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-024-00828-5 · Cited by 6
HIF1 activity in photoreceptors drives type 3 neovascularization and retinal atrophy in a new mouse model of age-related macular degeneration
Geiger, F., Heigl, T., Merolla, L., Yong, M., Wögenstein, G. M., Govers, L. P., Tsioti, I., Fottner, A., Samardzija, M., & Grimm, C. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08028-7 · Cited by 6
“The normoxic degradation of HIF1A is initiated by the hydroxylation of two prolines (P402 and P564 in humans; P402 and P577 in mice) in the oxygen dependent degradation domain (ODDD) of the protein [20], and mediated by the von Hippel Lindau (VHL) protein complex [21].”
A genome-scale single-cell CRISPRi map of trans gene regulation across human pluripotent stem cell lines
Feng, C., Peets, E. M., Zhou, Y., Crepaldi, L., Usluer, S., Dunham, A. S., Braunger, J. M., Su, J., Strauß, M. E., Muraro, D., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.101076 · Cited by 14
“…partner ARNT caused down-expres-sion of the glycolysis genes LDHA , GAPDH , and ALDOA , while knockdown of the HIF1A degradation gene VHL resulted in the up-regulation of these genes, thus recovering the regulative relationship between hypoxia and the glycolysis pathways 47,48 (Figures 2H and S4A).”
A Rare Presentation of Metastatic Renal Cell Carcinoma Masquerading as Vitritis: A Case Report and Review of Literature
Estopinal, M. D. V., Swan, R. T., & Rosenberg, K. I. (2022) · Diagnostics · doi:10.3390/diagnostics12071712 · Cited by 5
“RCC is a well-known malignancy for inducing upregulated angiogenesis and hemorrhagic metastases related to alterations in pVHL [1,12].”
Background
Interaction Among Noncoding RNAs, DNA Damage Reactions, and Genomic Instability in the Hypoxic Tumor: Is it Therapeutically Exploitable Practice?
Ray, S. K., & Mukherjee, S. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220120123557 · Cited by 5
Modified Hypoxia-Inducible Factor Expression in CD8+ T Cells Increases Antitumor Efficacy
Johnson, R. S., Veliça, P., Cunha, P. P., Vojnovic, N., Foskolou, I. P., Bargiela, D., Gojković, M., & Rundqvist, H. (2021) · Apollo (University of Cambridge) · doi:10.17863/cam.65798 · Cited by 5
A genome-scale single cell CRISPRi map of trans gene regulation across human pluripotent stem cell linesPreprint
Feng, C., Peets, E. M., Zhou, Y., Crepaldi, L., Usluer, S., Dunham, A. S., Braunger, J. M., Su, J., Strauß, M. E., Muraro, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.28.625833 · Cited by 5
Hypoxia-inducible factors (HIFs) in early pregnancy: implications for miscarriage
Lai, Y., Fu, Z., Gao, Y., Ma, N., & Li, L. (2024) · Biology of Reproduction · doi:10.1093/biolre/ioae139 · Cited by 4
“This enables the E3 ubiquitin ligase complex, which is gathered by the von Hippel Lindau (VHL) tumor suppressor, to ubiquitinate HIF-α and target it for proteasome degradation [32, 34, 35].”
Application of CRISPR-Cas9 Screening Technologies to Study Mitochondrial Biology in Healthy and Disease States
Sharon, D. M., & Chan, S. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8367-0_15 · Cited by 4
ACY-241, a histone deacetylase 6 inhibitor, suppresses the epithelial–mesenchymal transition in lung cancer cells by downregulating hypoxia-inducible factor-1 alpha
Park, S., Lee, N., & Jeong, C. (2023) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2024.28.1.83 · Cited by 4
“Typically, in the presence of oxygen, prolyl hydroxylase induces HIF-1 α hydroxylation, which is known to induce its proteasomal degradation mediated by the E3 ubiquitin ligase, von-Hippel Lindau tumor suppressor [25].”
Background
The von Hippel-Lindau protein forms fibrillar amyloid assemblies that are mitigated by the anti-amyloid molecule Purpurin
Kumar, V., Kaushik, V., Kumar, S., Levkovich, S. A., Gupta, P., Bar‐Yosef, D. L., Gazit, E., & Segal, D. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149250 · Cited by 3
Clinical decision making in small non-functioning VHL-related incidentalomas
Därr, R., Kater, J., Sekula, P., Bausch, B., Krauß, T., Bode, C., Walz, G., Neumann, H. P. H., & Zschiedrich, S. (2020) · Endocrine Connections · doi:10.1530/ec-20-0208 · Cited by 3
eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by small molecules
Purdy, S. C., Matlin, K., Alderman, C., Baldwin, A., Shrivastava, N., Sarioglu, G., Dutta, S., Webb, K. J., Wolin, A. R., Boulton, D. P., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116643 · Cited by 2
“70 Interestingly, two studies discovered that eIF3b, another subunit within the eIF3 complex, can directly bind to proteins to prevent their ubiquitination and subsequent degradation.”
Evaluation of the diagnostic utility of NCOA3, Maspin and VHL protein expression in pancreatic ductal adenocarcinoma: An immunohistochemical study
Elkady, N., Elgendy, W., Badr, M. T., Aiad, H. A. S., Samara, M. Y., & Badr, N. M. (2024) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2024.152356 · Cited by 2
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma
Giri, V. K., & Zaemes, J. P. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2468765 · Cited by 2
Dual Inhibition of HIF-1α and HIF-2α as a Promising Treatment for VHL-Associated Hemangioblastomas: A Pilot Study Using Patient-Derived Primary Cell Cultures
Moratalla, A. B. P., Carrión, B., Heras, K. V. G. D. L., Arias-Salazar, L., Yélamos-Sanz, B., Segura, T., & Serrano‐Heras, G. (2025) · Biomedicines · doi:10.3390/biomedicines13051234 · Cited by 2
“In VHL-deficient cells, the absence of functional VHL protein prevents the degradation of both HIF-α isoforms [20,25,30–32].”
Overexpression of BDNF and uPA Combined with the Suppression of Von Hippel–Lindau Tumor Suppressor Enhances the Neuroprotective Activity of the Secretome of Human Mesenchymal Stromal Cells in the Model of Intracerebral Hemorrhage
Станиславович, Д. С., Primak, A. L., Basalova, N. A., Kalinina, N., Monakova, A., Дмитриевич, Б. К., Velichko, A., Illarionova, M. E., Grigorieva, O., Akopyan, Z. A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146697 · Cited by 2
“VHL (Von Hippel–Lindau) is a negative master regulator of HIF proteins, a family of transcription factors [20,21], inducing cell metabolism adaptation and expression of a wide range of pro-angiogenic molecules (VEGF, erythropoietin, angiopoietins 1/2, PlGF, HGF, etc.) in response to hypoxia [22,23].”
Metabolic Reprogramming in Kidney Cancer: Implications for Therapy
Edo, E. T. (2025) · annals of urologic oncology · doi:10.32948/auo.2025.06.02 · Cited by 2
“The frequent loss of VHL and subsequent HIF stabilization upregulate glutamine transporters (ASCT2, SN2) and key enzymes like glutaminase (GLS), which converts glutamine to glutamate [38].”
Ischemic preconditioning in hepatic ischemic–reperfusion injury
Kuo, S.-C., Liu, Y., Tsai, C., & Sheen‐Chen, S. (2016) · Formosan Journal of Surgery · doi:10.1016/j.fjs.2016.03.003 · Cited by 2
Effect of hypoxia on HIF-1α and NOS3 expressions in CD34+ cells of JAK2V617F-positive myeloproliferative neoplasms
Şoroğlu, C. V., Uslu-Bıçak, İ., Toprak, S. F., Yavuz, A. S., & Sözer, S. (2023) · Advances in Medical Sciences · doi:10.1016/j.advms.2023.03.003 · Cited by 2
NF-ĸΒ1 knockout reduces IL6 expression under hypoxia in renal cell carcinoma
Teixeira, L. F. S., & Bellini, M. H. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.6.2 · Cited by 2
“Furthermore, the authors showed that the induction of NF-κB by tumor necrosis factor promotes an increase in the expression and activity of HIF-1α under hypoxic conditions [17-20].”
Background
Hypoxia in the Pathophysiology of Inflammatory Bowel Disease
Morales, M., & Xue, X. (2023) · Comprehensive physiology · doi:10.1002/cphy.c220002 · Cited by 3
“PHDs hydroxy-late proline residues in the HIF proteins in the presence of oxygen, which recruits the E3 ubiquitin ligase von-Hippel Lindau (VHL) tumor suppressor to enable ubiquitination and proteasomal degradation of the HIF proteins (39).”
A Corticotropin-Secreting Adenoma in the Setting of von Hippel-Lindau Disease
Chen, X., Zhou, Y., Lü, L., Feng, M., Wang, L., & Tong, A. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf055 · Cited by 1
“VHL disease results from germline pathogenic variants in the VHL tumor-suppressor gene on chromosome 3p25-p26 [5].”
Molecular dynamics reveal potential effects of novel VHL variants on VHL-Elongin C binding in ccRCC patients from Eastern India
Chatterjee, S., Paul, N., Das, A., Bank, S., Bankura, B., Yadav, R. P., Sarkar, K., Saha, S., Malakar, S., Choudhury, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-95875-1 · Cited by 1
“In hypoxic settings, HIF-1α remains unhydroxylated, inhibiting negative regulation by pVHL, which allows active HIF-1α to promote the expression of hypoxia-related genes 14,15 .”
VHL Suppresses Angiogenesis Through HIF-1a-Mediated Ang/Tie2/AMPK/VEGF Signaling Pathway in Tie-2 Expressed Macrophages (TEMs)
Zou, M.-C., Yang, Y., Mao, Y.-P., Liu, Y., Gao, H.-B., Liu, W.-D., Liu, J., & Zhang, F.-Y. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11175-3 · Cited by 1
“This aligns with previous reports demonstrating that VHL regulates angiogenesis by targeting HIF-1 α for ubiquitin-dependent degradation under normoxic conditions (Haase 2009).”
Von Hippel-Lindau disease: pathophysiological and clinical advances
van Alfen, S. J., van der Tuin, K., van de Kooij, B., Links, T. P., & Zandee, W. T. (2026) · Familial Cancer · doi:10.1007/s10689-026-00579-8 · Cited by 1
“HIFs have several oncogenic properties that underly the increased risk for tumor formation as observed in VHL disease [9–11 , 13].”
Colorectal Cancer Risk in Relation to Hypoxia Inducible Factor-1α (Hif-1 α) and Von Hippel-Lindau (Vhl) Gene Polymorphisms.
Demirel, S. (2017) · International Journal of Hematology and Oncology · doi:10.4999/uhod.171674 · Cited by 1
When rare diseases crisscross within the same patient: von Hippel-Lindau and type 1 gastric neuroendocrine tumor
Alexandraki, K., Spyroglou, A., Xekouki, P., Bramis, K., Kyriakopoulos, G., Barkas, K., Papanikolaou, I. S., Mastorakos, G. P., & Konstadoulakis, M. M. (2024) · HORMONES · doi:10.1007/s42000-024-00556-9 · Cited by 1
“Therefore, it appears important to perform further clinical, biochemical, and imaging screening in patients presenting with clear cell NENs before excluding VHL disease [16].”
BackgroundResult
Comparative Analysis of Gene Expression at Sea Level and High Altitude: A Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Approach
Alharthi, S. B., Alsubai, A. H., Almalki, S. K., El‐Shehawi, A. M., Eldebsy, A. M., Alsoliman, A. A., Alharthi, R. F., Morsi, M., Alharthi, D. R., & Mutabaqani, R. A. (2024) · Cureus · doi:10.7759/cureus.72489 · Cited by 1
“The outcome of this research work will add to human adaptation in high-altitude environments and further knowledge on hypoxia-related health conditions [2,5].”
Connexin 41.8 governs timely haematopoietic stem and progenitor cell specification
Petzold, T., Brivio, S., Linnerz, T., Watanabe, M., Gerhardt, H., & Bertrand, J. Y. (2025) · Biology Open · doi:10.1242/bio.062118 · Cited by 1
“This point is also valid for the data quantified FigS4 in which the fitting between WISH data and the quantifications appears to be questionable (for all timing points: 30, 32, 36, 48hpf and comparing mutant with WT).”
Intraoral Excision and Preoperative Embolization of a Von Hippel-Lindau Disease–associated Facial Arteriovenous Malformation
Moorthy, M., Loh, C. Y. Y., Drake, W. M., Morris, P. D., & Srirangalingam, U. (2020) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000002808 · Cited by 1
Modified Hypoxia Inducible Factor expression in CD8+ T cells increases anti-tumor efficacyPreprint
Veliça, P., Cunha, P. P., Vojnovic, N., Foskolou, I. P., Bargiela, D., Gojković, M., Rundqvist, H., & Johnson, R. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.18.159137 · Cited by 1
Data from TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling
Zhang, X., Li, S., He, J., Jin, Y., Zhang, R., Dong, W., Lin, M., Yang, Y., Tian, T., Zhou, Y., et al. (2023) · doi:10.1158/0008-5472.c.6513850.v1 · Cited by 1
Exploiting the Bioenergetics of Disease-Causing Lymphocytes for Selective Immunomodulation.
Wahl, D. R. (2012) · Deep Blue (University of Michigan)
Sporadic RCC: Abnormalities in Histone-Modifying Genes
Dere, R., & Ho, T. H. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1622-1_6
Variants of Hepatobiliary Angiomatous Tumors
Zimmermann, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-26587-2_50-1
Avaliação da capacidade angiogênica da linhagem celular de adenocarcinoma renal humano knockout para a proteína NF-kB1
da Silva, L. F. T. (2021) · doi:10.11606/d.85.2021.tde-22102021-122216
Redox regulation of the tumor suppressor p53
Shi, T. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/966
Variants of Hepatobiliary Angiomatous Tumors
Zimmermann, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-26956-6_50
Phacomatoses, genetic testing for personalisation of clinical management (part 2)
Kofla-Dłubacz, A., Stawarski, A., Pytrus, T., & Gil, J. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.2022.0007
Investigations into the pharmacological action of vioprolide A on inflammatory and angiogenic processes in endothelial cells
Burgers, L. D. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.68198
HIF-1α/LAPTM5/STAT1 axis promotes the malignant progression of clear cell renal cell carcinomaPreprint
Li, Y.-L., Zhang, M.-M., Zhang, Z., Cheng, J., Xu, W.-Y., Yan, K.-Y., Liu, Y.-H., Zhang, H.-Q., & Zhang, C. (2023) · Research Square · doi:10.21203/rs.3.rs-3300556/v1
The identification of novel genes involved in copper and oxygen metabolism
Gudekar, N. (2020) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/88873
Inhibitors of CK2 Kinase for the Treatment of Gliomas and Other Brain Tumors
Pucko, E. B., & Ostrowski, R. P. (2024) · Acta Poloniae Pharmaceutica - Drug Research · doi:10.32383/appdr/183629
Design and characterization of multiplex gene-edited CAR-T cells resistant to orthogonal immunosuppressive pathways within the solid tumor microenvironment
Murray, R. C. (2024) · Digital Repository Service (Northeastern University) · doi:10.17760/d20653008
Molecular Docking and Dynamic Simulation Studies of PHD2 Interactions with Gut Siderophores: Implications for HIF-1α StabilizationPreprint
Patel, J. I. A., Kurdekar, N. M., Padakannaya, A., Javaregowda, P. K., Khandagale, A. S., Joshi, C. G., Math, R. K., Majalakere, K., & Poyya, J. (2024) · Research Square · doi:10.21203/rs.3.rs-3714812/v1
Tratamiento farmacológico de las neoplasias asociadas con la enfermedad de von Hippel-Lindau. Revisión Sistemática
Hurtado, V. H., Mañay, C. E. C., & Aguilar, P. T. (2025) · Oncología (Ecuador) · doi:10.33821/765
Spinal Cord Tumors, Biology of
Salama, A., Salama, H. Z., Shimony, N., & Jallo, G. I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00338-9
VEGF/VEGFR: A Novel Therapy Target in Cancer
Wanode, D. M., Nandurkar, D., Palekar, R., Bhendarkar, K. P., & Khedekar, P. B. (2025) · Current Cancer Therapy Reviews · doi:10.2174/0115733947341681241209082508
Hereditary Renal Cell Carcinoma
Wang, M. X., Diab, M., Klekers, A. R., & Elsayes, K. M. (2025) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2025.06.002
APP ubiquitination by VHL protein is essential for MVB sorting and lysosomal degradation
Shan, C., Cong, R., Xu, X., Li, Y., Tian, Y., Cao, W., Zhao, W., Miao, L., Teng, J., Huang, N., et al. (2025) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaf033
“VHL syndrome is a rare familial disease characterized by the development of tumors in multiple organs, such as heman-gioblastomas of the retina and central nervous system (Haase, 2009 ).”
Belzutifan: a first-in-class oral HIF-2α inhibitor approved for patients with von Hippel-Lindau disease-associated renal cell carcinoma
Lu, Y., Yan, Z., Lyu, X., Zhang, S., & Zhao, Y. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00043-3
Preclinical evidence for digoxin’s anti-tumor activity through HIF-1α pathways: Systematic review and meta-analysis
Bolar, D., Viswanatha, G. L., Rao, C. M., Hanumanthappa, S., Nandakumar, K., & Nayak, P. G. (2026) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2026.100619
Disrupting E3 ubiquitin ligase protein–protein interactions in cancer: chemical modalities, mechanisms, and therapeutic opportunities
Kamel, E. M., Khadrawy, S. M., Ali, M. A. M., Ahmed, N. A., Yassin, N. Y. S., Alkhedhairi, S., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117951
Overcoming chemoresistance in esophageal cancer with synergistic strategies
Gao, C., Zhang, T., Li, G., Zhang, W., Chen, H., Li, D., Xu, J., Li, M., Wang, R., Xing, Y., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1784325
Alternative Splicing in Human Viral Oncogenesis and Tumor Progression
Martelli, I., Cappabianca, L. A., Cipriani, P., Farina, A. R., Sbaffone, M., & Mackay, A. R. (2026) · Cancers · doi:10.3390/cancers18122004
“It is highly plausible, therefore, that this may involve oncovirus-induced aberrant splicing of the VHL tumor suppressor, a master regulator of HIF [208], resulting in exon skipping and loss of function VHL isoforms, similar to those described in von Hippel–Lindau disease [209], in addition to…”
Die Rolle des CSB-Proteins bei der neuronalen Entwicklung und Hypoxie-induzierten Transkription
Schumacher, C. M. (2012) · Univ. Duesseldorf: Duesseldorfer Dokumenten- und Publikationsserver

Authors: Haase, V.
Affiliations: Vanderbilt University Medical Center (US)
Corresponding author: Haase, Volker
ORCID: Haase, Volker
Venue: Current Pharmaceutical Design
Publisher: Bentham Science Publishers Ltd.
Published: 2009-11-01
Volume: 15
Issue: 33
Pages: 3895-3903
ISSN: 1381-6128 (ISSN-L)
DOI: 10.2174/138161209789649394
PMC: PMC3622710
OpenAlex: W2067955850
Cited by: 175
References: 114
Citations by year: 2026: 5 · 2025: 27 · 2024: 19 · 2023: 21 · 2022: 20 · 2021: 18 · 2020: 10 · 2019: 9 · 2018: 5 · 2017: 4 · 2016: 9 · 2015: 5 · 2014: 8 · 2013: 6 · 2012: 5
FWCI: 1.01
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Current Pharmaceutical Design (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA100787)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080821, R01DK081646)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Health Sciences › Medicine › Oncology › Ear and Head Tumors
Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Keywords: von Hippel-Lindau tumor suppressor, hypoxia-inducible factor, ubiquitin ligase, proteasomal degradation, oxygen sensing, hemangioblastoma, clear cell renal cell carcinoma, pheochromocytoma, erythrocytosis, HIF-targeted therapy
MeSH terms: Animals, Humans, Mutation, Phenotype, Drug Delivery Systems, Gene Targeting, Mice, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit, Ubiquitination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The VHL Tumor Suppressor: Master Regulator of HIF

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks